CA2915027A1 - Compositions et procedes d'administration de vaccins contre le virus de la dengue - Google Patents

Compositions et procedes d'administration de vaccins contre le virus de la dengue Download PDF

Info

Publication number
CA2915027A1
CA2915027A1 CA2915027A CA2915027A CA2915027A1 CA 2915027 A1 CA2915027 A1 CA 2915027A1 CA 2915027 A CA2915027 A CA 2915027A CA 2915027 A CA2915027 A CA 2915027A CA 2915027 A1 CA2915027 A1 CA 2915027A1
Authority
CA
Canada
Prior art keywords
dengue virus
administration
compositions
methods
vaccines against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2915027A
Other languages
English (en)
Inventor
Dan T. Stinchcomb
Jorge E. Osorio
Charalambos D. Partidos
Joseph N. Brewoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CA2915027A1 publication Critical patent/CA2915027A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2915027A 2012-06-10 2013-06-10 Compositions et procedes d'administration de vaccins contre le virus de la dengue Abandoned CA2915027A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/492,884 2012-06-10
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus
PCT/US2013/045041 WO2013188315A1 (fr) 2012-06-10 2013-06-10 Compositions et procédés d'administration de vaccins contre le virus de la dengue

Publications (1)

Publication Number Publication Date
CA2915027A1 true CA2915027A1 (fr) 2013-12-19

Family

ID=48652375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915027A Abandoned CA2915027A1 (fr) 2012-06-10 2013-06-10 Compositions et procedes d'administration de vaccins contre le virus de la dengue

Country Status (6)

Country Link
EP (1) EP2858668A1 (fr)
JP (2) JP2015520196A (fr)
CA (1) CA2915027A1 (fr)
NZ (1) NZ630831A (fr)
TW (1) TW201402143A (fr)
WO (1) WO2013188315A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
CA3177572C (fr) 2013-03-15 2026-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions et procedes pour constructions chimeriques du virus de la dengue dans des vaccins
WO2017004567A1 (fr) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions et procédés pour polythérapie utilisant le virus de la dengue et des cellules dendritiques
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
EP3442571A1 (fr) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions et procédés de vaccination contre le virus de la dengue chez des enfants et de jeunes adultes
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (fr) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. Compositions et méthodes de thérapie avec le virus de la dengue
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US9211323B2 (en) * 2009-06-01 2015-12-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus

Also Published As

Publication number Publication date
JP2018090618A (ja) 2018-06-14
TW201402143A (zh) 2014-01-16
WO2013188315A1 (fr) 2013-12-19
NZ630831A (en) 2019-02-22
EP2858668A1 (fr) 2015-04-15
JP2015520196A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
EP4357355A3 (fr) Purification de virus
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
EP2471926A3 (fr) Oligodésoxynucléotides immunostimulateurs
WO2011103453A3 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
WO2014205389A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
WO2012024621A3 (fr) Vaccins à nanosupport synthétique comprenant des peptides obtenus ou dérivés de l'hémagglutinine du virus de la grippe a humaine
JP2012143233A5 (fr)
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
PT2940014T (pt) Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
WO2016019134A8 (fr) Agents à base de flagelline et utilisations comportant une vaccination efficace
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
EP2897640A4 (fr) Protéine c ur du virus de l'hépatite b, protéine antigénique de surface, et vaccin comprenant celles-ci
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP3010536A4 (fr) Compositions de vaccin contre le virus de la dengue, et leurs procédés d'utilisation
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2014140166A3 (fr) Vaccin
WO2013012835A3 (fr) Arnsi utile dans le traitement d'infection par flavivirus
BR112014020184A8 (pt) Preparação farmacêutica que contém anlodipina e ra-mipril
EP4226936A3 (fr) Virus non neuro-invasifs et leurs utilisations
WO2014167582A3 (fr) Composition de vaccin contre la prophylaxie chez des ruminants

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151210

FZDE Dead

Effective date: 20200831